Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 2Multiple Myeloma 2Wilms Tumor 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Carcinoma, Merkel Cell 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

pembrolizumab 6Nivolumab 6Ipilimumab 4Radiotherapy 3talimogene laherparepvec 2budigalimab 2avelumab 2atezolizumab 2Everolimus 2Cyclophosphamide 2zimberelimab 1venetoclax 1vatalanib 1tremelimumab 1temsirolimus 1sapanisertib 1rovalpituzumab tesirine 1poly ICLC 1oblimersen 1lorvotuzumab mertansine 1lanreotide 1glucopyranosyl lipid-A 1fludarabine 1durvalumab 1domatinostat 1cixutumumab 1cemiplimab 1aldesleukin 1Vinorelbine 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Merkel Cell × lorvotuzumab mertansine × Clear all
NCT00346385 2015-03-26

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors

ImmunoGen, Inc.

Phase 1 Completed
97 enrolled
DermatologicGynecologicThoracic

Ovarian Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡